Andrew Schwab, Director, Ten Percent Owner at Flexion Therapeutics, holds 9.68M shares in Skye Bioscience (Ticker: SKYE), holds 2.63M shares in CAMP4 Therapeutics Corporation (Ticker: CAMP), holds 960.38K shares in Enliven Therapeutics (Ticker: ELVN). Most recently, Andrew Schwab Sold ― shares of Skye Bioscience on Aug 22, 2025 for an estimated value of $800.55K.
Andrew Schwab latest transaction was an Informative Sell of $800.55K.
What was Andrew Schwab's most profitable transaction?
Andrew Schwab’s most profitable transaction was an Informative Buy of ~FLXN stock on February 11, 2014. The return on the trade was 57.30%.
What is Andrew Schwab's role in Flexion Therapeutics?
Andrew Schwab's role in Flexion Therapeutics is Director, Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.